IQVIA Holdings, Inc.
IQV · NYSE
Analyst Consensus
Analyst Ratings Synthesis
The supplied consensus is Buy across 17 analysts, with a mean price target of $275. No low or high target was provided, so the target cluster and width of the spread cannot be assessed. The evidence also identifies no individual analyst or firm, meaning the most and least bullish views cannot be named. No rating or target revisions were explicitly reported during the past week. The substantive disagreement in the available research is operational and financial: Zacks points to the proprietary data platform, expanding clinical research business, earnings beat, record bookings, and higher 2026 guidance as growth supports, while also highlighting high debt and liquidity risks. Execution and backlog conversion therefore remain the central counterweight to the bullish consensus.
- Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
- Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
- An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know
- An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know
- An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
Rating Actions
Research Reports
- Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
- Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
- An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know
- An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know
- An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
